胸腺肽α1对高龄患者消化系统肿瘤的临床效果研究

Clinical effects of thymosin α1 on gastrointestinal carcinoma in elderly patients

目的研究胸腺肽α1对高龄消化系统恶性肿瘤患者的临床疗效。方法选取湖北省黄岗市中心医院2010年2月-2012年6月收治的192例临床资料较为完整的老年消化系统肿瘤患者作为研究对象,随机分为对照组和治疗组,每组96例。对对照组进行化疗,同时皮下注射生理盐水,116 mg/次,每2 d一次,连续治疗8周;对治疗组进行化疗,同时皮下注射胸腺肽α1,116mg/次,每2 d一次,连续治疗8周。对所有患者进行T细胞亚群和NK淋巴细胞活性监测,监测时间为治疗前1周和治疗第2、4、8周,同时对比治疗前后两组患者的体力情况,进行Karnofsky评分比较。结果治疗前,治疗组与对照组各免疫指标差异均无统计学意义(P>0.05)。治疗后,治疗组CD4+、CD4+/CD8+和NK淋巴细胞指标明显高于对照组,差异均有统计学意义(P均<0.05);CD3+、CD8+指标差异均无统计学意义(P均>0.05)。治疗组治疗后CD4+、CD4+/CD8+和NK淋巴细胞指标明显高于治疗前,差异有统计学意义(P<0.05)。治疗前后对所有患者进行Karnofsky评分比较,治疗后治疗组平均评分明显高于对照组,差异有统计学意义(P<0.05);所有患者体力情况随治疗时间延长均有所下降,对照组患者治疗前后评分比较差异有显著统计学意义(P<0.01)。结论胸腺肽α1对提高患者的免疫指数具有显著效果,对患者体力下降的情况具有明显的抑制作用,对高龄患者消化系统肿瘤的临床效果显著。

Objective To evaluate the clinical effects of thymosin α1 on gastrointestinal carcinoma in elderly patients.Methods A total of 192 cases of elderly patients with digestive system tumors were selected as the research object,and randomly divided into control group and treatment group,ninety-six patients in each group.The control group received chemotherapy and each 2 days a saline injection,injection amount was 116 mg/time,course of treatment was 8 weeks.The treatment group received chemotherapy and 116 mg thymosin α1 hypodermic injection treatment,once 2 days,course of treatment was 8 weeks.T cell subgroup and NK lymphocyte activity were monitored before 1 week and after 2,4,8 weeks treatment.The patients＇ physical condition,Karnofsky score were compared.Results There was no significant difference in immune indexes between treatment group and control group before treatment （P ＞ 0.05）.After treatment,CD4＋,CD4＋/CD8＋ and NK lymphocyte indicators were significantly higher in treatment group than those in control group （P ＜ 0.05） ; but there were not significantly different in CD3 ＋,CD8 ＋ indicators between the two groups （P ＞ 0.05）.After treatment,CD4 ＋,CD4 ＋/CD8 ＋ and NK lymphocyte index were significantly higher than those before treatment in treatment group （P ＜ 0.05）.Karnofsky score was significantly higher in treatment group than that in the control group after treatment,the difference was statistically significant （P ＜ 0.05） ; physical situation of all patients with the treatment time were decreased,the grade was significant difference before and after treatment in control group （P ＜0.01）.Conclusion Thymosin α1 can improve the immunological function,it also can be used as an adjunctive drug for the gastrointestinal carcinoma in elderly patients.